A detailed history of Cetera Investment Advisers transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 31,893 shares of CPRX stock, worth $688,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,893
Previous 33,946 6.05%
Holding current value
$688,888
Previous $525,000 20.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.19 - $21.35 $31,185 - $43,831
-2,053 Reduced 6.05%
31,893 $634,000
Q2 2024

Aug 22, 2024

BUY
$14.68 - $16.92 $76,291 - $87,933
5,197 Added 18.08%
33,946 $525,000
Q1 2024

May 24, 2024

BUY
$13.18 - $17.11 $378,911 - $491,895
28,749 New
28,749 $458,000
Q4 2023

Feb 13, 2024

BUY
$11.78 - $17.29 $76,958 - $112,955
6,533 Added 42.75%
21,816 $366,000
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $701 - $901
60 Added 0.39%
15,283 $178,000
Q2 2023

Aug 09, 2023

BUY
$11.5 - $18.08 $12,604 - $19,815
1,096 Added 7.76%
15,223 $204,000
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $16,161 - $23,723
1,127 Added 8.67%
14,127 $234,000
Q4 2022

Feb 14, 2023

BUY
$12.25 - $19.5 $159,250 - $253,500
13,000 New
13,000 $241,000
Q1 2022

May 13, 2022

SELL
$5.31 - $8.31 $2,001 - $3,132
-377 Reduced 2.14%
17,275 $143,000
Q2 2021

Aug 13, 2021

BUY
$4.29 - $6.05 $2,329 - $3,285
543 Added 3.17%
17,652 $101,000
Q1 2021

May 17, 2021

BUY
$3.45 - $4.69 $376 - $511
109 Added 0.64%
17,109 $79,000
Q4 2020

Feb 17, 2021

BUY
$2.97 - $3.83 $50,490 - $65,110
17,000 New
17,000 $57,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.22B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.